308 related articles for article (PubMed ID: 2865252)
1. Maintenance therapy and the natural course of schizophrenia.
Davis JM
J Clin Psychiatry; 1985 Nov; 46(11 Pt 2):18-21. PubMed ID: 2865252
[TBL] [Abstract][Full Text] [Related]
2. Relapse prevention and recovery in the treatment of schizophrenia.
Schooler NR
J Clin Psychiatry; 2006; 67 Suppl 5():19-23. PubMed ID: 16822093
[TBL] [Abstract][Full Text] [Related]
3. Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications: a 15-year multifollow-up study.
Harrow M; Jobe TH
J Nerv Ment Dis; 2007 May; 195(5):406-14. PubMed ID: 17502806
[TBL] [Abstract][Full Text] [Related]
4. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
Woods SW; Gueorguieva RV; Baker CB; Makuch RW
Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
[TBL] [Abstract][Full Text] [Related]
5. Reducing the dose of depot neuroleptics in stable schizophrenia.
Dale R; Longdon M; Seeman MV
J Psychiatry Neurosci; 1994 Jul; 19(4):278-81. PubMed ID: 7918349
[TBL] [Abstract][Full Text] [Related]
6. The natural course of schizophrenia and effective maintenance drug treatment.
Davis JM; Andriukaitis S
J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):2S-10S. PubMed ID: 2870087
[TBL] [Abstract][Full Text] [Related]
7. A study of the pharmacologic treatment of medication-compliant schizophrenics who relapse.
Steingard S; Allen M; Schooler NR
J Clin Psychiatry; 1994 Nov; 55(11):470-2. PubMed ID: 7989278
[TBL] [Abstract][Full Text] [Related]
8. Duration of neuroleptic treatment and relapse rate: a 5-year follow-up study with haloperidol decanoate.
Youssef HA
Clin Neuropharmacol; 1991; 14 Suppl 2():S16-21; discussion S22-3. PubMed ID: 1684308
[TBL] [Abstract][Full Text] [Related]
9. Antipsychotic medication in the treatment of schizophrenia.
Kane JM
Isr J Psychiatry Relat Sci; 1995; 32(1):30-7. PubMed ID: 7542642
[TBL] [Abstract][Full Text] [Related]
10. Choice of maintenance medication for schizophrenia.
Davis JM; Chen N
J Clin Psychiatry; 2003; 64 Suppl 16():24-33. PubMed ID: 14680416
[TBL] [Abstract][Full Text] [Related]
11. Conventional versus novel antipsychotics: changing concepts and clinical implications.
Remington G; Chong SA
J Psychiatry Neurosci; 1999 Nov; 24(5):431-41. PubMed ID: 10586534
[TBL] [Abstract][Full Text] [Related]
12. [Discontinuation of antipsychotic drugs in chronic schizophrenic patients. II. Psychological and psychopathological test differences between patients with and without relapse].
Woggon B; Bickel P; Schnyder B
Int Pharmacopsychiatry; 1979; 14(5):278-93. PubMed ID: 43849
[TBL] [Abstract][Full Text] [Related]
13. Treating prodromal episodes to prevent relapse in schizophrenia.
Herz MI; Glazer W; Mirza M; Mostert M; Hafez H
Br J Psychiatry Suppl; 1989 Jul; (5):123-7. PubMed ID: 2574984
[No Abstract] [Full Text] [Related]
14. Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.
Fowler JA; Bettinger TL; Argo TR
Clin Ther; 2008 Feb; 30(2):231-48. PubMed ID: 18343262
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia.
Nasrallah HA; Tandon R
J Clin Psychiatry; 2002; 63 Suppl 13():12-20. PubMed ID: 12562142
[TBL] [Abstract][Full Text] [Related]
16. Early neuroleptic intervention in schizophrenia: are prodromal symptoms valid predictors of relapse?
Gaebel W; Frick U; Köpcke W; Linden M; Müller P; Müller-Spahn F; Pietzcker A; Tegeler J
Br J Psychiatry Suppl; 1993 Sep; (21):8-12. PubMed ID: 8105814
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity of treatment effects in schizophrenia.
Stroup TS
Am J Med; 2007 Apr; 120(4 Suppl 1):S26-31. PubMed ID: 17403379
[TBL] [Abstract][Full Text] [Related]
18. Interictal psychoses in comparison with schizophrenia--a prospective study.
Tadokoro Y; Oshima T; Kanemoto K
Epilepsia; 2007 Dec; 48(12):2345-51. PubMed ID: 17666070
[TBL] [Abstract][Full Text] [Related]
19. Relapse and therapeutic interventions in a 1-year observational cohort study of nonadherent outpatients with schizophrenia.
Ciudad A; San L; Bernardo M; Olivares JM; Polavieja P; Valladares A; Gilaberte I
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Mar; 36(2):245-50. PubMed ID: 22056291
[TBL] [Abstract][Full Text] [Related]
20. [Problems in evaluating new antipsychotic drugs].
Fleischhacker WW
Wien Med Wochenschr; 1998; 148(11-12):266-72. PubMed ID: 9746969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
